title: TNF-alpha antibody treatment in refractory collagenous sprue: report of a case and review of the literature.
abstract: Collagenous sprue (CS) is a rare disease characterized by celiac type small bowel malabsorption that is resistant to gluten free diet (GFD) and is associated with a poor prognosis. Our aim was to assess the properties of the monoclonal TNF-alpha antibody infliximab in a patient with high-dose steroid refractory CS. A 27-year-old man developed watery diarrhea with weight loss and abdominal pain. Duodenal biopsies showed a subtotal villous atrophy with an extensive subepithelial layer of collagenous fibers. An apparent GFD did not reduce symptoms. High dose steroid treatment (75 mg prednisone) in combination with azathioprine (150 mg) reduced diarrhea but did not induce complete remission. Based on strongly elevated mucosal TNF-alpha transcript concentrations we introduced infliximab (5 mg/kg body weight) into therapy. After two applications the patient's symptoms quickly improved. During the following year no recurrence of diarrhea has been observed. This case suggests that infliximab is an effective treatment in complicated cases of collagenous sprue.
authors.affiliation: Clinic of Internal Medicine, Department of Gastroenterology, Hepatology and Infectiology, Friedrich-Schiller-University, Jena. carsten.schmidt@med.unijena.de
authors.forename: C
authors.initials: C
authors.lastname: Schmidt
authors.forename: E
authors.initials: E
authors.lastname: Kasim
authors.forename: W
authors.initials: W
authors.lastname: Schlake
authors.forename: G
authors.initials: G
authors.lastname: Gerken
authors.forename: T
authors.initials: T
authors.lastname: Giese
authors.forename: A
authors.initials: A
authors.lastname: Stallmach
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000276:immunology; D002446:Celiac Disease / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology; D002908:Chronic Disease; D004351:Drug Resistance; D006801:Humans; D000069285:Infliximab; D008297:Male; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab